Navigation Links
Halozyme Announces Proposed Public Offering of Common Stock
Date:2/9/2012

documents that Halozyme has filed, or will file, with the SEC for more complete information about Halozyme and this offering. You may access these documents, when available, free of charge by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, you may obtain a preliminary prospectus supplement and accompanying prospectus as indicated above.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets HYLENEX® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the public offering) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
2. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
3. Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting
4. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
5. Halozyme Begins Randomized, Controlled Clinical Trial with PEGPH20 in Patients with Advanced Pancreatic Cancer
6. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
7. Halozyme Therapeutics to Present at Upcoming Financial Conferences
8. Halozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17
9. Halozymes Ultrafast Insulin Demonstrates Reduced Variability of Insulin Absorption for Type 1 Diabetes Patients Using Insulin Pumps
10. Halozyme and Intrexon Announce Collaboration to Develop First Subcutaneous Recombinant Alpha 1-Antitrypsin Replacement Therapy
11. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... -- Sony Biotechnology Inc. ("Sony") today announced the launch of the ... chip.  Sony will also be exhibiting its newly rebranded reagent ... the EC800 flow cytometer, and new SP6800 Spectral Analyzer will ... be held at the San Diego ... from May 20 - 22.  The 8-well ...
(Date:5/17/2013)... , May 17, 2013  TechAtlas Group ... for their competitive landscape map for the Chronic ... over 90 international companies with drugs and devices ... CKD and its sequelae. (Logo:  ... , hypertension - renal denervation ...
(Date:5/17/2013)... LAKES, Fla. , May 17, 2013 Fuse ... and delivery technology company that is developing new, patent-pending technologies ... minerals, announced today that it will hold a business update ... Wednesday, May 22 nd , 2013 at 4:30 PM ET. ... Tuffin will host the call and will be ...
Breaking Medicine Technology:Sony Delivers New Technology for Science to CYTO 2013 2TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2
... -- China Health Resource, Inc. (OTCBB: CHRI), today announced results ... the first quarter of 2012. Revenues for ... increase of 234% over revenues of US $10,282,207 for 2010. For ... common share, compared with a net income of $2,707,286, or ...
... Oncos Therapeutics today announced the successful initiation ... adenovirus suggested as a potential new treatment for many types ... safety assessment part of the study. " We ... r thern Europe to start a clinical study with ...
Cached Medicine Technology:China Health Resource Reports on Record Year-End 2011 Results Continuing Strong in 2012 2China Health Resource Reports on Record Year-End 2011 Results Continuing Strong in 2012 3Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers 2
(Date:5/18/2013)... The “World Healthcare IT Market: Trends & ... market drivers, restraints, and opportunities in North America, Europe, ... 89 market data tables , ... IT Market" , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , ... The global healthcare IT market is expected to grow ...
(Date:5/18/2013)... After working diligently for months and putting in a ... integration of the fitment specs for the redesigned 2012 Hyundai ... the automobile market with its extraordinary features and unique combination ... the latest entry in the size it up ... year 2013. , Aptly suiting its name, 2012 Hyundai ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 TheBeautyPlace.com answers ... Pattern hair loss is not a result of stress, ... to Men’s Fitness Magazine, 70% of men suffer from ... Strength is renowned for hair transplant surgery, but ... male pattern baldness known as Bosley Professional Strength. Their ...
(Date:5/18/2013)... Family Magazine of Washington DC was awarded the "Best ... Inc. in the category of Summer Camps in DC ... the areas best in the ultimate guide on parenting, kids ... Brenda Hyde, a mother of four and publisher of Family ... vast resources available to them in the DC Metro area. ...
(Date:5/18/2013)... New York (PRWEB) May 18, 2013 ... mount in courts throughout the country, Bernstein Liebhard LLP ... hip replacement patients often suffer tissue damage before they ... study, which according to Science Daily will appear in ... hip replacement recipients underwent MRI screens of their hips. ...
Breaking Medicine News(10 mins):Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 3Health News:Summer Camps in DC "Best of the Best" Awarded to Family Magazine of Washington DC for Excellence by Follow Media Consulting, Inc. 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4
... 29, 2009) The allergen breathed in by a person ... activates a cascade of events to prompt an allergic reaction, ... Medicine ( www.bcm.edu ) in Houston in a report that ... , In particular, MMP7 activates interleukin 25, a key mediator ...
... shortness of breath and trimmed hospital stays, phase 2 study ... relaxin reduces shortness of breath and cardiovascular death in people ... to a phase 2 trial conducted in eight countries. ... hours of arriving at a hospital, were randomly assigned to ...
... to clean equipment regularly with alcohol wipes , , ... three stethoscopes used by U.S. emergency medical service ... bacteria, a new study suggests. , Researchers at ... Jersey swabbed 50 stethoscopes used by independent emergency ...
... recently reported on new Baxter Heparin testing standards that are to ... following several deaths after the contaminated drug was used on patients, ... an ingredient that caused the deaths of several and sickened hundreds. ... ...
... M.D., MPH, co-director of the National Center for Vermiculite ... Cancer Institute in Detroit, MI, and chief of the ... University , announced the use of a new technology ... The announcement was made at the Asbestos Disease Awareness ...
... In what has quickly evolved into a historic ... in Northwestern Minnesota and Eastern North Dakota, is ... the region. Despite rising flood waters and disrupted ... are still accepting patients, according to officials. To ...
Cached Medicine News:Health News:Hormone Reduces Mortality in Heart Patients With High BP 2Health News:Third of EMS Stethoscopes Carry MRSA Bacterium 2Health News:LegalView Informs Baxter Heparin Patients of New Testing Standards for Blood Thinner Following Deaths From Previous Contamination 2Health News:LegalView Informs Baxter Heparin Patients of New Testing Standards for Blood Thinner Following Deaths From Previous Contamination 3Health News:LegalView Informs Baxter Heparin Patients of New Testing Standards for Blood Thinner Following Deaths From Previous Contamination 4Health News:New Tool in the Radiography Approach Will Assist in Earlier Detection of Asbestos-Related Diseases 2Health News:New Tool in the Radiography Approach Will Assist in Earlier Detection of Asbestos-Related Diseases 3Health News:Innovis Health Continues to Serve Region 2
Provides a combination of concentrated cold / hot and compression for the neck...
Provides a combination of concentrated cold / hot and compression for the back...
... One-Piece™ Collar is completely injected molded from ... our patented chin support. , ,Our ... efficiently managed where space is limited. Color-coded ... of sizes., ,Either in a supine ...
... optional hot and cold therapy Gel Pad. Our ... providing cold therapy to reduce swelling and /or ... recovery., ,To order hot and cold therapy ... number., ,Our suspenders can be added to ...
Medicine Products: